PM Modi Chairs High-Level Meeting To Review Oxygen Supply, Stresses On Coordination With 'Vibrant' Pharma Sector
Prime Minister Narendra Modi chaired a high-level meeting to review the availability and supply of medical oxygen along with medicines that are being used for the treatment of COVID patients.
New Delhi: Prime Minister Narendra Modi on Wednesday chaired a high-level meeting to review the availability and supply of medical oxygen and medicines that are being used for the treatment of COVID patients.
PM Modi was given inputs of the situation wherein the government is in regular touch with the manufacturers to enhance the production of medicines and extend all help needed.
ALSO READ | BJP Clears Air On Centre's Vaccine Export, Says 84% Doses Sent Abroad Part Of Licensing Liabilities
The Prime Minister was informed that centre is actively monitoring the supply of medicines being used in the management of COVID as well as mucormycosis. He was apprised about the current production and stock of APIs for each such drug and that states are being provided medicines in good quantities.
The production of all drugs including Remdesivir has been ramped up significantly in the last few weeks.
"India has a very vibrant pharma sector and the government's continued close coordination with them will ensure proper availability of all medicines," the Prime Minister said.
Besides antiviral drugs, PM Modi sought details about the situation with respect to oxygen availability and supply in the country.
He was informed that the supply of oxygen is now more than three times the supply during the peak of the first wave.
The Prime Minister was briefed about the operations of Oxygen Expresses and sorties by IAF planes. He was also informed about the status of procurement of oxygen concentrators, oxygen cylinders as well as the status of PSA plants being installed across the country.
He also remarked that states should be asked to operationalise ventilators in a time-bound manner and resolve technical and training issues with the help of the manufacturers.
(With Agency Inputs)